Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2534-2542

  Chen, J Q ^a,b   Bao, Y ^a,b   Lee, J ^c   Murray, J L ^a   Litton, J K ^a   Xiao, L ^d,e   Zhou, R ^f   Wu, Y ^d   Shen, X Y ^f   Zhang, H ^d   Sahin, A A ^d   Katz, R L ^d   Bondy, M L ^f   Berinstein, N L ^g   Hortobagyi, G N ^a   Radvanyi, L G ^a,b  

^a Departments of Breast Medical Oncology   (United States)

^b Departments of Melanoma Medical Oncology   (United States)

^c Genetic Regulatory Networks   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY   (China)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Breast cancer; Immunohistochemistry; Prognostic marker; Trps 1

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; TRANSCRIPTION FACTOR GATA; TRICHORHINOPHALANGEAL SYNDROME 1 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE MARKER; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL RATE;

BREAST CANCER; IMMUNOHISTOCHEMISTRY; PROGNOSTIC MARKER; TRPS-1;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884722769     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt190     Document Type: Article

References (52)

1. Radvanyi L, Singh-Sandhu D, Gallichan S et al. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA 2005; 102: 11005-11010.
2. Chen JQ, Litton J, Xiao L et al. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. Horm Cancer 2010; 1: 21-33.
3. Chen JQ, Bao Y, Litton J et al. Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer. Horm Cancer 2011; 2: 132-143.
4. Momeni P, Glockner G, Schmidt O et al. Mutations in a new gene, encoding a zinc-finger protein, cause tricho-rhino-phalangeal syndrome type I. Nat Genet 2000; 24: 71-74.
5. Chang GT, van den Bemd GJ, Jhamai M et al Structure and function of GC79/TRPS1, a novel androgen-repressible apoptosis gene. Apoptosis 2002; 7: 13-21.
6. Malik TH, Von Stechow D, Bronson RT et al Deletion of the GATA domain of TRPS1 causes an absence of facial hair and provides new insights into the bone disorder in inherited tricho-rhino-phalangeal syndromes. Mol Cell Biol 2002; 22: 8592-8600.
7. Gai Z, Gui T, Muragaki Y. The function of TRPS1 in the development and differentiation of bone, kidney, and hair follicles. Histol Histopathol 2011; 26: 915-921.
8. Malik TH, Shoichet SA, Latham P et al. Transcriptional repression and developmental functions of the atypical vertebrate GATA protein TRPS1. EMBO J 2001; 20: 1715-1725.
9. Piscopo DM, Johansen EB, Derynck R. Identification of the GATA factor TRPS1 as a repressor of the osteocalcin promoter. J Biol Chem 2009; 284: 31690-31703.
10. Wuelling M, Kaiser FJ, Buelens LA et al. Trps1, a regulator of chondrocyte proliferation and differentiation, interacts with the activator form of Gli3. Dev Biol 2009; 328: 40-53.
11. Kouros-Mehr H, Slorach EM, Sternlicht MD et al GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006; 127: 1041-1055.
12. Cavallaro U, Schaffhauser B, Christofori G. Cadherins and the tumour progression: is it all in a switch? Cancer Lett 2002; 176: 123-128.
13. Di Croce L, Pelicci PG. Tumour-associated hypermethylation: silencing E-cadherin expression enhances invasion and metastasis. Eur J Cancer 2003; 39: 413-414.
14. Gai Z, Zhou G, Itoh S et al. Trps1 functions downstream of Bmp7 in kidney development. J Am Soc Nephrol 2009; 20: 2403-2411.
15. Itoh S, Kanno S, Gai Z et al. Trps1 plays a pivotal role downstream of Gdf5 signaling in promoting chondrogenesis and apoptosis of ATDC5 cells. Genes Cells 2008; 13: 355-363.
16. Napierala D, Garcia-Rojas X, Sam K et al. Mutations and promoter SNPs in RUNX2, a transcriptional regulator of bone formation. Mol Genet Metab 2005; 86: 257-268.
17. Kaiser FJ, Moroy T, Chang GT et al. The RING finger protein RNF4, a co-regulator of transcription, interacts with the TRPS1 transcription factor. J Biol Chem 2003; 278: 38780-38785.
18. Stinson S, Lackner MR, Adai AT et al. TRPS1 Targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal 2011; 4: ra41.
19. Tomaskovic-Crook E, Thompson EW, Thiery JP. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 2009; 11: 213.
20. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
21. The world Health Organization histological typing of breast tumors-second edition. The World Organization. Am J Clin Pathol 1982; 78: 806-816.
22. Black MM, Speer FD. Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957; 105: 97-102.
23. Birner P, Oberhuber G, Stani J et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001; 7: 1669-1675.
24. WolffAC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
25. Tan PH, Bay BH, Yip G et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005; 18: 374-381.
26. Thike AA, Chng MJ, Fook-Chong S et al Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology 2001; 33: 21-25.
27. Bertolo C, Guerrero D, Vicente F et al. Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. Am J Clin Pathol 2008; 130: 414-424.
28. Tan DS, Potts HW, Leong AC et al. The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast. J Pathol 1999; 189: 20-27.
29. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527.
30. Irizarry RA, Hobbs B, Collin F et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
31. Nguyen PL, Taghian AG, Katz MS et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26: 2373-2378.
32. Gabos Z, Thoms J, Ghosh S et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat 2010; 124: 187-194.
33. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
34. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398.
35. Suemoto H, Muragaki Y, Nishioka K et al. Trps1 regulates proliferation and apoptosis of chondrocytes through Stat3 signaling. Dev Biol 2007; 312: 572-581.
36. Prat A, Parker JS, Karginova O et al Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
37. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
38. Asselin-Labat ML, Sutherland KD, Barker H et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007; 9: 201-209.
39. Hoch RV, Thompson DA, Baker RJ et al GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 1999; 84: 122-128.
40. Eeckhoute J, Keeton EK, Lupien M et al. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 2007; 67: 6477-6483.
41. Albergaria A, Paredes J, Sousa B et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res 2009; 11: R40.
42. Ciocca V, Daskalakis C, Ciocca RM et al. The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Hum Pathol 2009; 40: 489-495.
43. Mehra R, Varambally S, Ding L et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 2005; 65: 11259-11264.
44. Yoon NK, Maresh EL, Shen D et al. Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol 2010; 41: 1794-1801.
45. Taube JH, Herschkowitz JI, Komurov K et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010; 107: 15449-15454.
46. Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820-13825.
47. Venet D, Dumont JE, Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 2011; 7: e1002240.
48. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
49. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-1618.
50. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
51. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-tomesenchymal transition and stem cell characteristics. Cancer Res 2009; 69: 4116-4124.
52. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.